NBIX Neurocrine Biosciences Stock Forecast 2026: CNS Biopharma Beyond Ingrezza
NBIX Neurocrine Biosciences 2026 stock forecast: deep-dive into Ingrezza's tardive dyskinesia franchise durability, the Crenessity CAH launch, and whether this CNS biopharma can sustain its valuation as it transitions from one-product dependency to a multi-asset platform.
NBIX Neurocrine Biosciences CNS Biopharma